An Eye for an Eye: Lucentis and the New Pharmaceutical Value System
This article was originally published in RPM Report
A head- to- head trial of Genentech’s Avastin v. Lucentis raises the stakes in the debate over drug pricing. While previous large comparative trials have focused on a number of different drugs--old against new--the Avastin study is evaluating two brand new cutting edge technologies, one for off-label use. Genentech is not alone in finding this unsettling.
You may also be interested in...
On July 21, Roche reported strong first half sales of Lucentis. It was all downhill from there.
The long awaited head-to-head trial of Avastin vs. Lucentis in macular degeneration has finally reported results. It pits a $1,500 a dose therapy against a $50, unapproved alternative that most providers think is just as good. We just had that debate over Makena. Recent comments by FDA’s top drug review official suggest there may be another connection.
CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.